Bechstein W O, Dette K, Golling M, Wullstein Ch
Chirurgische Universitätsklinik, Ruhr Universität Bochum, Knappschaftskrankenhaus Bochum-Langendreer, In der Schornau 23-25, 44892 Bochum.
Kongressbd Dtsch Ges Chir Kongr. 2002;119:398-404.
Primary malignancy after solid organ transplantation has a more than three-fold incidence compared to the normal population. Causes are intensity and duration of immunosuppression, pre-operatively undetected, occult malignancy or pre-cancerous lesions in the recipient, direct or indirect tumor transmission via the transplant and environmental factors. Measures for prevention comprise antiviral treatment of individuals at risk for primary EBV-infection and prevention of sun exposure. Early detection follows general medical guidelines and, in addition, selective screening of certain risk groups of patients. Treatment of solid tumors follows established guidelines of professional working parties. Post-transplant lymphoproliferative disorders can often be treated with anti-CD antibody (rituximab). Antiproliferative immunosuppressants like rapamycin may seem promising with regard to a possibly reduced incidence of de-novo malignancy in the future.
